Drug intelligence / Profile preview

CELEXT-07

Development stage: Phase 2
Lead developer: 9305-9954 Quebec
Modality: Small Molecules
Administration: Topical

Overview

CELEXT-07 is a small molecule drug developed by Québec Inc for the topical treatment of onychomycosis (fungal infection of the toenails). It is currently in Phase 2 clinical trials for this indication. The drug is designed to be applied topically and has been evaluated in randomized, double-blind studies comparing its efficacy and safety to placebo and active controls. Its mechanism of action has not been explicitly detailed in public sources, but it is being investigated primarily for infectious diseases affecting skin and nails.

Beyond the preview

Go deeper on CELEXT-07.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CELEXT-07.

Explore the full profile